IDP-023
Phase 2Small molecule
IDP-023 is one of 10 small molecule programs targeting Hematologic Cancer. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
9 competitors in Hematologic Cancer
#DrugCompanyPhaseTrials
1Rituxan
RochePhase 2
Cytoxan
BBaxter Healthcare Corporation
Phase 2
Fludara
SanofiPhase 2
Darzalex
Johnson & JohnsonPhase 2
Sarclisa
AAzienda U.S.L. 1 di Massa e Carrara
Phase 2
Mesnex
BBaxter Healthcare Corporation
Phase 2
Venclexta
AbbViePhase 1
Interleukin 2
EEssen Biotech
Phase 2
IDP-023
IIndapta Therapeutics, INC.
Phase 2
ABBV-101
AbbViePhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for IDP-023. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- IIndapta Therapeutics, INC.